Company profile
Humacyte, Inc.
NASDAQ:HUMABiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07762313 | phase3 | not_yet_recruiting | 2026-09-01 | 2028-12-01 | Humacyte, Inc. | An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury. |
| NCT03183245 | phase3 | completed | 2017-09-29 | 2024-04-22 | Humacyte, Inc. | Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis |
| NCT02644941 | phase3 | completed | 2016-05-24 | 2019-05-01 | Humacyte, Inc. | Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis |
| NCT01872208 | — | completed | 2013-10-10 | 2016-05-30 | Humacyte, Inc. | Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD |
| NCT03005418 | phase2_3 | completed | 2018-09-01 | 2023-09-19 | Humacyte, Inc. | Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125812 | BLA | Humacyte Global Inc. | ||||
Loading… | ||||||